Cardiovascular disease is the number one killer in the world, and better treatments are in high demand. Swedish biotech company Cereno Scientific is developing new treatments for both common and rare cardiovascular diseases and will initiate a phase II trial with lead candidate CS1 in September this year. During 2021, the company has also strengthened the team, their IP and expanded their portfolio with two development programmes in close collaboration with the University of Michigan. BioStock has now published a status report that can be downloaded below.
Download the Cereno Scientific status report below.
This analysis is a Status Report by BioStock, conducted on commission by the analysed company. BioStock’s remuneration for the work has been agreed upon beforehand and is independent of the content and conclusions reached in the analysis. The content of this report is based solely on publicly available information gathered through research by the analyst from sources such as e.g., financial reports and statements, the company’s web page, public presentations and in dialogue with representatives of the company’s executive management. The information about the company was made available to the company for fact-checking and was published subsequent approval by the company. The analysis contains subjective assessments regarding future events and outcomes which should be considered to render such assessments to be uncertain. Any valuation of the company, products and/or markets has been made by BioStock’s analyst. The analyst does not own shares in the company. This status report should not be considered as a recommendation or advice to invest in the company, nor shall it be interpreted as financial advice of any sort. BioStock cannot and does not give any guarantees that the conclusions or forecasts presented in this report will be fulfilled. BioStock cannot be held responsible or liable for any damage, direct or indirect, caused by decisions made based on the information in this report. BioStock is not subject to the supervision of the Swedish financial authority Finansinspektionen and is thus not required to comply with the specific rules and guidelines that apply to analysis firms subject to the supervision of Finansinspektionen.